Compare · LONA vs SRPT

LONA vs SRPT

Side-by-side comparison of LeonaBio Inc. (LONA) and Sarepta Therapeutics Inc. (SRPT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. LONA focuses on Biotechnology: Biological Products (No Diagnostic Substances), while SRPT focuses on Biotechnology: Pharmaceutical Preparations.
  • SRPT is the larger of the two at $1.52B, about 47.2x LONA ($32.2M).
  • SRPT has been more active in the news (8 items in the past 4 weeks vs 7 for LONA).
  • SRPT has more recent analyst coverage (25 ratings vs 4 for LONA).
MetricLONASRPT
Company
LeonaBio Inc.
Sarepta Therapeutics Inc.
Price
-
-
Market cap
$32.2M
$1.52B
1M return
-46.42%
-
1Y return
-37.44%
-
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2020
News (4w)
7
8
Recent ratings
4
25
SRPT

Sarepta Therapeutics Inc.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Latest LONA

Latest SRPT